The United States has given its approval to the world’s first twice-a-year injection for HIV prevention, marking a significant step towards a global rollout that could safeguard millions.
The drug, lenacapavir, developed by Gilead Sciences, offers a powerful new option in the fight against the virus, though questions remain regarding its accessibility both within the US and internationally.
